Invention Grant
- Patent Title: Spirolactams as inhibitors of ROCK
-
Application No.: US16315678Application Date: 2017-07-06
-
Publication No.: US10696674B2Publication Date: 2020-06-30
- Inventor: Peter W. Glunz , Indawati DeLucca , Andrew K. Dilger
- Applicant: BRISTOL-MYERS SQUIBB COMPANY
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agent Hong Liu
- International Application: PCT/US2017/040850 WO 20170706
- International Announcement: WO2018/009625 WO 20180111
- Main IPC: C07D471/10
- IPC: C07D471/10 ; C07D401/14 ; C07D403/10 ; C07D487/10 ; C07D491/10

Abstract:
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
Public/Granted literature
- US20190322664A1 SPIROLACTAMS AS INHIBITORS OF ROCK Public/Granted day:2019-10-24
Information query